Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $20.89 Average Price Target from Analysts

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) have been assigned an average rating of "Buy" from the ten research firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, seven have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $20.89.

Several analysts recently commented on YMAB shares. Wedbush reaffirmed an "outperform" rating and set a $23.00 target price on shares of Y-mAbs Therapeutics in a report on Friday, January 10th. Brookline Capital Management began coverage on shares of Y-mAbs Therapeutics in a research report on Thursday, December 5th. They set a "buy" rating and a $17.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating and issued a $22.00 target price on shares of Y-mAbs Therapeutics in a research report on Monday, January 13th. Finally, Oppenheimer initiated coverage on Y-mAbs Therapeutics in a report on Monday, November 18th. They set an "outperform" rating and a $23.00 price target for the company.

Y-mAbs Therapeutics Trading Down 2.3 %

Shares of YMAB traded down $0.14 during mid-day trading on Tuesday, reaching $6.03. The company's stock had a trading volume of 586,562 shares, compared to its average volume of 441,214. Y-mAbs Therapeutics has a 1-year low of $5.71 and a 1-year high of $20.90. The business has a 50-day simple moving average of $7.90 and a two-hundred day simple moving average of $11.37. The stock has a market cap of $270.08 million, a P/E ratio of -11.17 and a beta of 0.67.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last announced its quarterly earnings results on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The business had revenue of $18.46 million for the quarter, compared to analyst estimates of $23.38 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same period in the prior year, the business earned ($0.18) EPS. Research analysts anticipate that Y-mAbs Therapeutics will post -0.64 EPS for the current year.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Y-mAbs Therapeutics in the third quarter worth $44,000. China Universal Asset Management Co. Ltd. increased its holdings in Y-mAbs Therapeutics by 66.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company's stock valued at $113,000 after buying an additional 3,416 shares during the period. Intech Investment Management LLC acquired a new position in shares of Y-mAbs Therapeutics in the 3rd quarter valued at approximately $133,000. SG Americas Securities LLC bought a new stake in shares of Y-mAbs Therapeutics during the 3rd quarter worth approximately $178,000. Finally, Empire Financial Management Company LLC acquired a new stake in shares of Y-mAbs Therapeutics during the 3rd quarter worth approximately $210,000. 70.85% of the stock is owned by institutional investors and hedge funds.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.